The Procurement Blind Spot in Hospital Operating Theatres
When the clinical trail is clear but the financial trail is not, where does the missing piece go?
How do you prove your hospital owes money for something it never actually bought? And how do you verify what a hospital owes for a device that was used before it was ever recorded as received?
These aren't hypothetical questions. They are everyday realities of high-value implant procurement, where the usual rules of buying and paying get turned upside down.
Consider the scenario: an implant is in the building, the surgeon uses it, and the clinical record tells us exactly what happened and to whom. So far, so good. Then the invoice arrives, and something is missing: the financial trail has a gap where the usual proof of receipt should be.
So where did the missing piece go? That is the procurement puzzle. But when the same gap can sit inside a hospital’s most expensive procurement category, it stops being a puzzle. It becomes an industry-wide financial control problem.
The Missing Link
For most hospital purchases, finance's basic control is the three-way match: an invoice clears only when it agrees with a purchase order and a record that the goods were received. However well or badly that runs in practice, it rests on one thing being true first: all three documents exist.
High-value implants don’t follow that sequence. They are held at the hospital on consignment, still owned by the supplier, and become a purchase only when a surgeon uses them. The device is therefore used first, with the receipt recorded afterwards, often after the invoice has already arrived. By the time the hospital owes the money, the document the usual verification depends on may not yet exist.
What exists instead is a record from the clinical workflow. Whether captured in the operating theatre and entered into the hospital information system or documented directly within it, its primary purpose is to support patient care, clinical documentation, and billing. It records which device was implanted, in whom, and supports the patient's medical record and insurance claim. But knowing that an implant was used is not the same as knowing what the hospital owes for it. It was never designed to establish what the hospital needs to pay its supplier.
A payable transaction turns on a different question. Finance needs to know the supplier has invoiced the right device, in the right quantity, at the contracted price and on the agreed terms. The clinical record answers the clinical half of that: which device, which patient, that it was used. The commercial half, the price and the terms, it was never built to hold. The contracted rate and any discounts or rebates live in the supplier agreement, not in the operating theatre.
The Systemic Gap
The problem gets harder at the point of care. A 2022 study in Health Care Management Science found that hospital staff accurately recorded between 45% and 95% of the items they used, depending on the department. That makes sense, after all, the person scanning an implant is caring for a patient, not reconciling a supplier invoice.
Hospitals have long had a reason to improve this process. But the two sides of the transaction create very different signals. If a device is used but never billed to the patient, the hospital sees an immediate revenue loss. This makes charge capture visible and measurable, and hospitals have invested heavily in improving documentation at the point of care.
A discrepancy on the supplier side is harder to see. The hospital may know what was used and what the vendor invoiced, but not whether the two should have matched in the first place. The real difficulty here is measuring what that gap actually costs. The hospital only has a record of where the implant was used, not the transaction itself, so it cannot say with any confidence what it lost.
The financial impact can be significant. A 2023 study in the Journal of Operations Management found that consignment did not save hospitals money on some of their most expensive items. The reason was simple: hospitals could not confirm what the vendor had supplied or what had actually been used. When consigned stock is not tracked as it is consumed, industry estimates put the loss at 5% to 15% of its value. Because the error is built into how the transaction works, there is no quick fix to apply to each implant purchase or use. The loss will recur every quarter until the process changes.
The Changing Economics
For a long time, hospitals had more room to absorb these losses, but two things have changed that.
One reason is tighter pricing. India’s National Pharmaceutical Pricing Authority has progressively tightened price controls on high-value medical devices, including a cap on the price of coronary stents and orthopaedic knee implants introduced in 2017, which has since been updated in April 2025. As reimbursement and pricing become more constrained, hospitals have less room to absorb discrepancies between what was used, what was invoiced, and what was paid. Errors that were once diluted across procurement spend now have a more direct effect on financial performance.
The second is greater financial scrutiny. Indian hospitals are drawing significant private capital, and the sector is moving onto the public markets at steep valuations. Manipal Hospitals, for example, now the country's largest chain by licensed bed capacity, listed in August 2026 at roughly $9 billion, a valuation that prices in years of future growth. For an investor or a buyer, an unmeasured loss is harder to assess than a known one. A hospital that cannot establish how much it is losing, or where the leakage occurs, carries an uncertainty that reads as financial risk, and that risk can weigh on valuation.
The question, then, is how to solve a problem that is built into the procurement process itself. The answer is not another layer of reconciliation at the end of the transaction, but to scrutinize the process itself.
The clinical record already captures the first part. What has been missing is the financial layer that makes that same event visible to procurement and finance.
Consignment was meant to take cost and risk off the hospital's books. On its most expensive items, it may be doing the opposite: leaving a large, recurring cost on the books that the hospital cannot see, price, or account for. The problem is not that money leaks. It is that the hospital cannot say how much, or where, or against what it should have been.
None of this needs to be taken on faith, but it does need to be measured: how much of this spend leaves the building unverified, and where. Until a hospital can establish what was used, at the price it agreed, at the moment it was used, every number that follows is an estimate. And an estimate is not something a hospital can defend, to a regulator or to a buyer.
